Simultaneous determination of abamectin homologs H ₂ B _1a and H ₂ B _1b in gel formulation by high performance liquid chromatography

ABSTRACT

Abamectin is a drug with antiparasitic properties used in several pharmaceutical formulations. The objective of this research was to develop and validate a high performance liquid chromatographic (HPLC) method for quantification of the two abamectin homologs (H₂B_1a and H₂B_1b) in gel formulation. This HPLC method was validated using a LichroCart^(r) 100 RP-18 (125 x 4 mm, 5 µm) column. The mobile phase contained of acetonitrile and water (95:5 v/v) with 1% acetic acid. The flow rate was 1.0 mL min^-1 and UV detection was performed at 245 nm. Mobile phase solutions were prepared containing a nominal concentration 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b. The method displayed good linearity in the concentration range of 148.1 - 222.3 µg mL^-1 and 7.7 - 11.5 µg mL^-1, for H₂B_1a and H₂B_1b, respectively, with a correlation coefficient of (r)> 0.99 for both compounds, calculated by the least mean squares method. Detection limits (DLs) were 2.8 µg mL^-1 and 1.2 µg mL^-1 and quantitation limits (QLs) were 8.6 µg mL^-1 and 3.8 µg mL^-1, for H₂B_1a and H₂B_1b, respectively. The method is simple, economical and efficient for the quantitative determination of abamectin H₂B_1a and H₂B_1b homologs in pharmaceutical preparations.

Uniterms:
Abamectin homologs/validation method/gel formulation; Abamectin homologs; High Perfomance Liquid Chromatography (HPLC).

INTRODUCTION

Avermectins are a group of fermentation products obtained from a strain of Streptomyces avermitilis and are 16-membered macrocyclic lactones, and comprise several derivatives including abamectin (Xie et al., 2011). Abamectin (Figure 1) is used in veterinary practice as an antiparasitic and in agriculture as an insecticide. Abamectin consists of a mixture of two homologous compounds: H₂B_1a (at least 80%) and avermectin H₂B_1b (no more than 20%) (Shoop, Mrozik, Fisher, 1995). Metabolic studies, have shown that abamectin H₂B_1b is generally metabolized more rapidly than the H₂B_1a homolog and therefore, H₂B_1a is the major residue found in tissues and biological fluids (Markus, Sherma, 1992). Abamectin was suspected causing adverse effects in the aquatic environment, even in low concentrations, as it presents high toxicity to aquatic organisms, such as fish and microcrustaceans (Tisler, Erzen, 2006). Several different methods have been reported in scientific literature for the analyses of abamectin, such as, high performance liquid chromatography (HPLC) (Kulik et al., 2011), liquid chromatography coupled to mass spectrometry (LC-MS) (Valenzuela et al., 2000; Pozo et al., 2003; Yoshii et al., 2004; Xiaolin et al., 2006; Thompson et al., 2009; Rübensam et al., 2011; Tao et al., 2012; Campillo et al., 2013; Ismail et al., 2013), HPLC with fluorescence (Diserens, Henzelin,1999; Souza et al., 2003; Kolar et al., 2004; Borges et al., 2008; Cerkvenik-Flajsa et al., 2010; Xie et al., 2011; Rahman et al., 2013), and UHPLC with fluorescence (Liu et al., 2001; Romero-González et al., 2011). The aim of this research was to validate a HPLC method for quantitative determination of abamectin homologs (H₂B_1a and H₂B_1b) in gel formulation, as this drug is widely used in veterinary practice. Abamectin consists of a mixture of two homologous compounds: H₂B_1a (at least 80%) and avermectin H₂B_1b (Shoop, Mrozik, Fisher, 1995). It is very important to separate and quantify both simultaneously since each homolog in abamectin has a specific concentration. The proposed method was developed and validated proposed to enable the separation and quantitative determination of the two abamectin homologs, in a short period of time; using a simple mobile phase in the chromatographic runs. The principal justification for this research was that there were very few methods described in literature for simultaneous quantitative determination of abamectin homologs, H₂B_1a and H₂B_1b. The proposed method presented a shorter analysis period compared to those described in literature, which is an advantage in quality control. It is a precise, and accurate method with can be used in routine analysis for quality control of gel formulation containing H₂B_1a and H₂B_1b.

FIGURE 1
Chemical structures the abamectin homologs (H₂B_1a and H₂B_1b) (Xie et al., 2011).

MATERIAL AND METHODS

Chemicals and reagents

A mixture (98.7% purity) of abamectin H₂B_1a (93.8%) and H₂B_1b (4.9%) was donated by a pharmaceutical company. The gel formulation was a commercially available preparation containing 1% abamectin/ 10 g. Placebo was prepared in the laboratory containing the following excipients: hydroxyethylcellulose (1.00 g), EDTA (0.10 g), methyl paraben (0.20 g) and propyl paraben (0.10 g), imidazolinidyl urea solution 50% (0.60 g) and distilled water q.s.p 100.00 g.

The chromatographic grade methanol and acetonitrile were purchased from J. T. Baker^(r) (Philipsburg, USA). Acetic acid was purchased from Vetec^(r) (Rio de Janeiro, Brazil). Ultrapure water was obtained by using a Milli-Q^(r) water purification system (Millipore^(r) Co., Milford, MA, USA).

The mobile phase consisted of acetonitrile and water (95:5 v/v) with 1% acetic acid. The flow rate was 1.0 mL min^-1 and UV detection was made at 245 nm. Solutions were prepared in the mobile phase containing 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 of H₂B_1b.

Instrumentation

The proposed HPLC quantitative method was developed using the following equipment a solvent-delivery system, an auto-injector fitted with a 20 µL loop, an online degasification system, a column thermostat oven and an ultraviolet/visible (UV/VIS) with photodiode array detector. The output signal was monitored and integrated using Class-VP^(r) 5.03 software (Shimadzu^(r) Corporation, Kyoto, Japan). The mobile phase was filtered through a 0.45 µm PTFE Millipore^(r) membrane (Millipore, Milford, USA). A Mettler AL204 analytical balance was used to weigh all compounds.

Procedures

Method validation

The method was validated according to the United States Pharmacopeia, 37^th ed. (USP, 2014) and International Conference on Harmonization Guidelines (ICH, 2005).

Analytical curves

Analytical curves for abamectin were obtained using five different concentration levels, in each of the following ranges: 148.1 - 222.3 µg mL^-1 and 7.7 - 11.5 µg mL^-1, for H₂B_1a and H₂B_1b, respectively. Standard solutions were diluted with mobile phase and determinations were made in triplicate.

System suitability

Standard solutions containing 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b abamectin were prepared by dilution in the mobile phase. System suitability was determined from ten replicate injections of each standard solution.

Precision

Precision was obtained by determining the repeatability and intermediate precision. Repeatability was tested by analyzing six replicates of sample a concentration of 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b. Intermediate precision was obtained by performing the analysis, in triplicate on two different days using different analysts, using sample solutions in a concentration of 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b. Solutions were filtered through a 0.45 µm Millipore^(r) (PTFE) membrane before injection into the HPLC system.

Accuracy

Accuracy was assessed by determining the agreement between measured analyte concentrations of fortified and unfortified sample when a known amount of standard was added to the sample.

A quantity of 25.0 mg of abamectin standard (H₂B_1a and H₂B_1b) was weighed and transferred to a 25 mL volumetric flask. After addition of 20 mL mobile phase, the solution was sonicated for 5 min. The volume was completed with the same solvent (solution A). Final concentration was 1000.0 µg mL^-1. Aliquots of 0.8, 1.0 and 1.2 mL were transferred to 5 mL volumetric flasks. The volumes were completed with mobile phase.

An amount equivalent to 25.0 mg of the placebo gel formulation was weighed and transferred to a 25 mL volumetric flask. After addition of 20 mL of mobile phase, the solution was sonicated for 5 min. The volume was completed with the same solvent (solution B). Aliquots of 1.0 mL were transferred to 5 mL volumetric flasks. The volumes were completed with mobile phase.

As described in RE 899 placebo solutions were fortified by transferring 1.0 mL of sample solution (solution B) to 5 mL volumetric flasks, followed by addition of 0.8, 1.0 and 1.2 mL of standard solution (solution A). The volumes were completed with ultrapure water. Solutions were filtered through a 0.45 µm Millipore^(r) (PTFE) membrane before injection into the HPLC system.

Stability test

Standard and sample solutions were prepared separately, as previously described, to obtain solutions containing 185.2 µg mL^-1 of H₂B_1a and 9.6 µg mL^-1 of H₂B_1b. These solutions were stored at 25°C and triplicate measurements were made during a period of 4 hours.

Robustness test

The UV detection wavelength and mobile phase composition were deliberately modified. Mobile phases consisted of acetonitrile and water (96:4 v/v) with 1% acetic acid and acetonitrile and water (94:6 v/v) with 1% acetic acid. UV detection was performed at 243 and 247 nm. The standard and sample solutions containing 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b were prepared by dilution in ultrapure water and injected in triplicate.

Stress testing

Stress testing was made as per Klick et al., 2005. Evaluation was performed in neutral hydrolysis, acid hydrolysis, alkaline hydrolysis and chemical oxidations.

Standard solution was prepared by transferring 25.0 mg of abamectin to a 25 mL volumetric flask. Sample solution was prepared by transferring 2500.0 mg of the gel formulation (equivalent to 25.0 mg of abamectin) to a 25 mL volumetric flask. To the standard and sample solutions, 20 mL of mobile phase were added and solutions sonicated for 5 min. Volume were completed with the same solvent. Aliquots of 1.0 mL of both solutions were transferred to 5 mL volumetric flasks. Neutral hydrolysis was performed by adding 1.0 mL of water, chemical oxidations were performed by adding 1.0 mL of 3% H₂O₂ solution_, acid hydrolysis was performed by adding 1.0 mL of 1 mol L^-1 HCl solution and alkaline hydrolysis was performed by adding 1.0 mL of 1 mol L^-1 NaOH solution. After cooling the volumes were completed with mobile phase. The solutions were heated to 80 ºC for 2 hours. The proposed method was used to analyze sample solutions in a concentration of 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b. Mobile phase was filtered through a 0.45 µm PTFE Millipore^(r) membrane (Millipore, Milford, USA).

RESULTS AND DISCUSSION

Ideal conditions for obtaining a good separation of abamectin homologs (H₂B_1a and H₂B_1b) were achieved using a mobile phase consisting of acetonitrile and water (95:5 v/v) with 1% acetic acid. It was observed that pH adjustment was not required because the final pH of the mobile phase (4.47) was favorable for use considering abamectin pka (Figure 2). Mean retention times (RT) for H₂B_1a and H₂B_1b were, 2.6 and 2.3 min, respectively. The resulting chromatograms can be observed in Figure 4.

FIGURE 2
Abamectin pkas observed in different pHs (Chemicalize, 2016).

FIGURE 3
Residual analysis of abamectin (H₂B_1a and H₂B_1b).

FIGURE 4
Chromatograms of placebo, standard, sample and mobile phase solutions. Chromatographic conditions: concentrations: 185.2 µg mL^-1 for H₂B_1a and 9.6 µg mL^-1 for H₂B_1b, column: LichroCart^(r) 100 RP-18 (125 x 4 mm, 5 µm), mobile phase: acetonitrile and water (95:5 v/v) with 1% acetic acid, flow rate: 1.0 mL min^-1, UV detection, at 245 nm and temperature, 25 ± 1 °C.

FIGURE 5
Representative chromatograms standard reference homologs and sample solutions after stress testing. Concentration: 185.2 µg mL^-1 H₂B_1a and 9.6 µg H₂B_1b. Chromatograms: initial condition (A), neutral hydrolysis (B), chemical oxidation (C), acid hydrolysis (D), and alkaline hydrolysis (E). Chromatographic conditions: same as described in Figure 2

Linearity

From analytical data, the responses obtained for the two homologs were linear in the concentration ranges from: 148.1- 222.3 µg mL^-1 and 7.7 - 11.5 µg mL^-1, for H₂B_1a and H₂B_1b, respectively. These ranges were used based on ICH (ICH, 2005) which indicates a range from 80 to 120% of the test concentration for the assay of a drug substance or a finished drug product. Correlation coefficients were 0.9961 for H₂B_1a and 0.9960 for H₂B_1b. The F Test was also performed which confirm the proportionality of linear regression, resulting from analysis of variance. The experimental value must be greater than the default value for a confidence level of 95 % (Pimentel, Barros Neto, 1996). The value obtained was 10 times larger than the standard value (6.39) (Table I).

TABLE I
Linear regression data obtained in the analyses of abamectin homologs H₂B_1a and H₂B_1b using the proposed HPLC method

Statistical parameters	H2B1a	H2B1b
Concentration range* (µg mL1)	148.1- 222.3	7.7 - 11.5
Regression equation	y= 32305x + 1x106	y= 15475x+133889
Correlation coefficient	0.9961	0.9960
Detection limit (µg mL-1)	2.8	1.2
Quantitation limit (µg mL-1)	8.6	3.8
F test * *	379.50	371.01

• * n= 5; * * value of 95%, 6.39.

As important as the F test is residual analysis (Figure 3), which demonstrates an optimal distribution of the results (Pimentel, Barros Neto, 1995).

System suitability

Standard solutions were injected, and relative standard deviations (RSD) for each parameter were determined. In all cases, RSD values were less than 2%, which proves the reliability of the proposed analytical method (Table II).

TABLE II
System suitability test results using final concentration of the sample solution: 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b

Parameters	H2B1a*	H2B1b*
Retention time	2.61± 0.38	2.28± 0.26
Area	6602238± 0.80	465191± 0.65
Peak height	854701± 0.84	24642± 0.68
Theoretical plates	4646± 0.48	4692± 0.51
Capacity factor	1.44± 0.45	1.13± 0.50
Assimetry	1.25± 0.00	1.33± 0.00

• * Average of 10 determinations

Precision

Precision was obtained by determining repeatability and intermediate precision. The repeatability was conducted by analyzing six replicates of the sample at the concentration of 85.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b. Relative standard deviation (RSD) was determined. Intermediate precision was obtained by analyzing triplicates of the sample in the concentration of 185.2 µg mL^-1 H₂B_1a and 9.6 µg mL^-1 H₂B_1b. The RSD was determined after triplicate analysis of samples on two different days using two different analysts. The method presented good results for precision (Table III).

TABLE III
Precision analysis results obtained for the proposed HPLC method for determining abamectin homologs H₂B_1a and H₂B_1b in gel formulation

Precision	H2B1a(%)	H2B1b (%)
Repeatability a	92.29 ± 0.65	6.37 ± 0.06
RSD (%)	0.88	1.16
Intermediate precision b	92.07± 0.01	6.43 ± 0.03
	93.52± 0.01	6.57 ± 0.08
Mean value	92.80	6.50
RSD (%)	1.10	1.52

• ^a
  arithmetic mean value (n = 6); ^b arithmetic mean value (n = 2)

Accuracy

Recovery was evaluated by adding known amounts of abamectin H₂B_1a and H₂B_1b standard solutions to the abamectin gel sample. Recovery was evaluated at three different concentration levels. Triplicate determinations were performed at each concentration. Average recoveries of 98.62% ± 0.23 for H₂B_1a and 100.06% ± 0.95 for H₂B_1b, at three different concentration levels were obtained, indicating good accuracy for the proposed chromatographic method (Table IV).

TABLE IV
Recovery results for abamectin H₂B_1a and H₂B_1b homolog standard solutions added to sample and analyzed by the proposed HPLC method

Compound	Added amount (µg mL-1 )	Found amount (µg mL-1 )	Recovery ( %)
H2 B1a	150.62 187.53 225.13	148.15 ± 0.77 185.26 ± 0.01 222.27 ± 1.04	98.36 98.79 98.72
H2 B1b	7.70 9.57 11.64	7.70 ± 0.07 9.67 ± 0.01 11.54 ± 0.01	100.00 101.04 99.14

Specificity

The placebo solution was prepared and analyzed using the proposed HPLC method. Results were compared with those obtained in the analyses of standard and sample. The excipients did not interfere in the method. The method was considered specific for the simultaneous determination of abamectin homologs H₂B_1a and H₂B_1b in gel formulation (Figure 4).

Detection limit (DL) and quantitation limit (QL)

The DL and QL were determined based on the standard deviation between response and slope of the curve. The theoretically obtained values for QL were cross-checked by performing analyses using the proposed HPLC method. DLs were 2.8 µg mL^-1 and 1.2 µg mL^-1, and QLs were 8.6 µg mL^-1 and 3.8 µg mL^-1, for H₂B_1a and H₂B_1b, respectively (Table I).

Stability of solutions

It is essential to evaluate the stability of standard and sample solutions to obtain reliable results. Standard and sample solutions were stored at 25 °C for 4 hours and after analyses the obtained results were compared with those obtained using freshly prepared solutions. No differences were observed in the instrumental responses under the described conditions. The RSDs obtained in the stability test were 1.19% and 0.44%, respectively for H₂B_1a and H₂B_1b (Table V), which were similar to those obtained using freshly prepared solutions.

TABLE V
Results from the stability test for abamectin H₂B_1a and H₂B_1b

Condition/RSD	H2B1a(%)a	H2B1b (%)a
Initial conditions	92.07± 0.01	6.43 ± 0.03
After stability test	93.63± 0.01	6.39 ± 0.01
RSD (%)	1.19	0.44

• ^a
  n= 3

Robustness

Deliberate changes in analytical parameters, did not lead to significant changes in the instrumental responses, and RSDs values were less than 2% in all cases. When the wavelength was changed to 243 nm, the obtained RSDs were 0.86% and 0.99% and when changed to 247 nm, were 0.47% and 1.74% for H₂B_1a and H₂B_1b, respectively. When mobile phase composition was changed to 96:4 v/v acetonitrile and water with 1% acetic acid, RSDs were 0.10% and 0.44% for H₂B_1a and H₂B_1b, respectively. When changed to 94:6 v/v acetonitrile and water with 1% acetic acid, RSDs were 0.62% and 0.88% for H₂B_1a and H₂B_1b, respectively. All results obtained in the robustness test were similar to those under initial conditions. Thus, the proposed method can be considered reliable and robust.

Stress testing

Stress testing studies are used to assess drug substance and drug product stability to provide information on possible degradation pathways, and to demonstrate the stability-indicating capability of the analysis methods used. These studies are performed under more drastic conditions than those used for accelerated stability tests (Klick et al., 2005). Stress testing was conducted using neutral, acid and alkaline hydrolysis and chemical oxidation. After chemical oxidation and neutral hydrolysis, the results showed no significant changes in peak degradation, however, a different retention time was observed for the H₂B_1a standard substance. After both acid and alkaline hydrolysis, degradation was observed in both standard and sample substances (Figure 4).

The proposed method was appropriate for determining of abamectin homologs, H₂B_1a and H₂B_{1b ,} in the presence of their degradation products, since all compounds could be separated, as seen in the chromatograms. Thus, the proposed HPLC method can be used in quality control as a stability- indicating method.

CONCLUSION

There are few methods described in literature for simultaneous quantitative determination of abamectin homologs H₂B_1a and H₂B_1b. Most methods described in literature just quantify total abamectin fraction.

The proposed HPLC method is simple, economic and efficient for the separation and quantitative determination of the two homologs in gel formulation, and can thus be considered an important tool in quality control. The advantage of the proposed method over those described in scientific literature is the speed, leading to economy of solvents. It is very important to quantify these homologs as abamectin was identified as probable cause of adverse effects in the aquatic environment, even when present in low concentrations (Cerkvenik-Flajsa et al., 2010). The excipients did not interfere in the analyses proving that the method presents selectivity. The proposed HPLC method proved to be useful and reliable and can be used to indicate the stability of routine analyses in quality control laboratories.

REFERENCES

• BORGES, J.H.; RAVELO-PÉREZ, L.M.; HERMÁNDEZ-SUÁREZ, E.M.; CARNERO, A.; RODRIGUÉZ-DELGADO, M. A. Determination of abamectin residues in avocados by microwave-assisted extraction and HPLC with fluorescence detection. Chromatogr., v.67, p.69-75, 2008.
• CAMPILO, N.; VIÑAS, P.; FEREZ-MELGAREJO, G.; HERMÁNDEZ-CORDOBA, M. Dispersive liquid-liquid microextraction for the determination of macrocyclic lactones in milk by liquid chromatography with diode array detection and atmospheric pressure chemical ionization ion-trap tandem mass spectrometry. J. Chromatogr. A, v.1282, p.20-26, 2013.
• CERKVENIK-FLAJSA, V.; MILCINSKIA, L.; SUSSINGERA, A.; HODOSCEKA, L.; DANAHERB, M.; ANTONÍC, J. Trace analysis of endectocides in milk by high performance liquid chromatography with fluorescence detection. Anal. Chim. Acta, v.663, p.165-171, 2010.
• CHEMICALIZE. Abamectin. 2016. Disponível em: <http:// http://www.chemicalize.org/structure/#!mol=abamectin&source=fp>. Acesso em: 01 abr. 2016.
  » http:// http://www.chemicalize.org/structure/#!mol=abamectin&source=fp
• DISERENS, H.; HENZELIN, M. Determination of abamectin residues in fruits and vegetables by high-performance liquid chromatography J. Chromatogr. A, v.833, p.13-18, 1999.
• INTERNATIONAL CONFERENCE ON HARMONISATION. ICH. Validation of Analytical Procedures: Text and methodology Q2(R1). Geneva: ICH, 2005. Available at: <http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf>. Accessed on: 16 Jul. 2015.
  » http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf
• ISMAIL, R.; LEE, H.Y.; MAHYUDIN, N.A.; BAKAR, F.A. Linearity study on detection and quantification limits for the determination of avermectins using linear regression. J. Food Drug Anal., v.22, p.407-412, 2014.
• KLICK, S.; PIM, G.; MUIJSELAAR.; WATERVAL, J.; EICHINGER, T.; KORN, C.; GERDING, G.K.; DEBETS, A.J.; GRIEND, C.S.; BELD, C.; SOMSEN, G.W.; JONG.; C.J. Toward a generic approach for stress testing of drug substances and drug products. Pharm. Technol., v.29, p.48-66, 2005.
• KOLAR, L.; KUZNER, J.; ERZEN, N.K. Determination of abamectin and doramectin in sheep faeces using HPLC with fluorescence detection. Biomed. Chromatogr., v.18, p.117-124, 2004.
• KULIK, A.; SZC OTKOWSKA, A.; BIALECKA, W.; PODOLKA, M.; KWIATKOW-PUCHNIARZ, B.; MAZUREK, A. Determination of active substances in binary mixture antiparasitc veterinary by HPLC. Acta Pol. Pharm., v.68, p.467-472, 2011.
• LIU, H.; ZHANG, Y.; LIU, L.; LI, Q.; SHAO, J.; ZOU, Y. Fast separation ultra-performance liquid chromatography for determination of pre-column derivative abamectin and ivermectin residues in vegetable. J. Fluoresc., v.21, p.825-829, 2011.
• MARKUS, J.; SHERMA, J. Liquid chromatography fluorescence determination of ivermectin in animal tissue and plasma. J. AOAC Int., v.75, p.757-767, 1992.
• PIMENTEL, M.F.; BARROS NETO, B. Calibração: uma revisão para químicos analíticos. Quím. Nova, v.19, n.3, p.268-277, 1996.
• POZO, O.J.; J. MARIN, J. M.; SANCHO, J.V.; HERNÁNDEZ, F. Determination of abamectin and azadirachtin residues in orange samples by liquid chromatography-electrospray tandem mass spectrometry J. Chromatogr. A, v.992, p.133-140, 2003.
• RAHMAN, M.M.; NA, T.W.; EL-ATY.; PARK, J.H.; MAHMUD, M.N.U.; YANG, A.; PARK, K.H.; SHIM, J.H. Dissipation pattern and pre-harvest residue limit of abamectin in perilla leaves. Environ. Monit. Assess., v.185, p.9461-9469, 2013.
• ROMERO-GONZÁLEZ, R.; AGUILERA-LUIZ, M.M.; PLAZA-BOLÃNOS, P.; FRENICH, AG.; VIDAL, J.L.M. Food contaminant analysis at high resolution mass spectrometry: application for the determination of veterinary drugs in milk. J. Chromatogr. A, v.1218, p.9353-9365, 2011.
• RÜBENSAM, G.; BARRETO, F.; HOOF, R.B.; KIST, T.L.; PIZZOLATO, T.M. A liquid-liquid extraction procedure followed by a low temperature purification step for the analysis of macrocyclic lactones in milk by liquid chromatography-tandem mass spectrometry and fluorescence detection. Anal. Chim. Acta, v.705, p.24-29, 2011.
• SOUZA, S.V.C.; SILVA, G.; DINIZ, M.H.G.M.; SANTOS, E.V.; LIMA, J.A.; TEODORO, J.C. Determination of avermectins residues in bovine liver by high performance liquid chromatography. Ciênc. Tecnol. Alim., v.23, p.54-58, 2003.
• SHOOP, W.L.; MROZIK, H.; FISHER, M.H. Structure and activity of avermectins and milbemycins in animal health. Vet. Parasitol., v.59, p.139-156, 1995.
• TAO, Y.; YU, G.; CHEN, D.; PAN, Y.; LIU, Z.; WEI, H.; PENG, D.; HUANG, L.; WANG, Y.; YUAN, Z. Determination of 17 macrolide antibiotics and avermectins residues in meat with accelerated solvent extraction by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B, v. 897, p. 64-71, 2012.
• THOMPSON, T.S.; NOOT, D.K.; FORREST, F.; HEEVER, J.P.V.D.; KENDALL, J.; KEENLISIDE, J. Large volume injection for the direct analysis of ionophores and avermectins in surface water by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal. Chim. Acta, v.633, p.127-135, 2009.
• TISLER, T.; ERZEN, N.K. Abamectin in the aquatic environment. Ecotoxicology, v.15, p.495-502, 2006.
• UNITED STATES PHARMACOPEIA. USP. 37. ed. Rockville, United States: Pharmacopeial Convention, 2014. p.1157-1162.
• VALENZUELA, A.I.; REDONDO, M.J.; PICO, Y.; FONT, G. Determination of abamectin in citrus fruits by liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. A, v.871, p.57-65, 2000.
• XIAOLIN, H.; JIANG, H.; DING, S.; ZHAND, S.; LI, X.; SHEN, J. Multiresidue analysis of avermectins in cattle liver by liquid chromatography/ tandem mass spectrometry. J. AOAC Int., v.89, p.1110-1115, 2006.
• XIE, X.; GONG, S.; WANG, X.; WU, Y.; ZHAO, L. Simplified RP-HPLC method for multi-residue analysis of abamectin, emamectin benzoate and ivermectin in rice. Food Addit. Contam., v.28, p.19-25, 2011.
• YOSHII, K.; ISHIMITZU, S.; TONOGAI, Y.; ARAKAWA, K.; MURATA, H.; MIKAMI, H. Simultaneous determination of emamectin, its metabolites, mibemectin, ivermectin and abamectin, in Japanese radish and tea by LC/MS. J. Health Sci., v.50, p.17-24, 2004.

Publication Dates

• Publication in this collection
  Sept 2016

History

• Received
  03 Oct 2015
• Accepted
  03 June 2016